---
title: "Achieve Life Sciences Adds Director Amid Board Transitions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286099106.md"
description: "Achieve Life Sciences has appointed Christopher Martin to its board as part of ongoing transitions, with a $40,000 retainer and stock options. Long-time chairman Thomas King will resign on June 8, with Lucian Iancovici, MD, taking over. Chief Commercial Officer Jaime Xinos will leave on May 31, as the company reorganizes ahead of the cytisinicline launch. Analysts rate ACHV stock as a Buy with a $13.00 target, though Spark's AI Analyst gives it a Neutral score due to weak financials and cash burn, despite regulatory progress and financing improvements."
datetime: "2026-05-12T12:16:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286099106.md)
  - [en](https://longbridge.com/en/news/286099106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286099106.md)
---

# Achieve Life Sciences Adds Director Amid Board Transitions

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Achieve Life Sciences ( (ACHV) ) has issued an update.

On May 11, 2026, Achieve Life Sciences appointed Christopher Martin to its board under a designation right linked to a recent private placement, granting him standard non-employee director compensation, including a pro-rated $40,000 retainer and stock options vesting over three years. The company agreed to nominate Martin for re-election at its 2026 and 2027 annual meetings while Frazier Life Sciences maintains a significant stake, signaling investors’ deeper governance role.

Board changes continued with long-time director and chairman Thomas King notifying the company on May 7, 2026 that he will resign effective June 8, after which director Lucian Iancovici, MD, will assume the chair role. In a further leadership shift, Chief Commercial Officer Jaime Xinos will leave Achieve effective May 31, 2026, with severance under her employment agreement, as the company reorganizes its commercial leadership ahead of an anticipated cytisinicline launch, underscoring a broader governance and executive refresh during a critical pre-commercial phase.

The most recent analyst rating on (ACHV) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.

**Spark’s Take on ACHV Stock**

According to Spark, TipRanks’ AI Analyst, ACHV is a Neutral.

The score is held down primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn). Partially offsetting this are tangible regulatory progress and a major financing event that improves the company’s ability to fund trials and commercialization, while technical indicators remain mixed and valuation lacks profitability or dividend support.

To see Spark’s full report on ACHV stock, click here.

**More about Achieve Life Sciences**

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline, a plant-based investigational therapy for nicotine dependence. The company is targeting both smoking and vaping cessation, supported by Phase 3 data for smoking cessation and Phase 2 data in vaping, and is preparing for potential U.S. commercialization pending regulatory approval.

**Average Trading Volume:** 1,061,851

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $534.9M

### Related Stocks

- [ACHV.US](https://longbridge.com/en/quote/ACHV.US.md)

## Related News & Research

- [Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News](https://longbridge.com/en/news/286952863.md)
- [Achieve Life Sciences Announces Up to $354 Million Private Placement | ACHV Stock News](https://longbridge.com/en/news/283004765.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Jacobs Growth Could Improve on Data Centers, Life Sciences Demand, RBC Says](https://longbridge.com/en/news/286945689.md)